WESTMINSTER, Colo., Feb 03, 2010 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics, today announced that members of the Company's
senior management will present on Monday, February 8, at 2:30 p.m. EST
at the 12th Annual BIO CEO & Investor Conference taking place
at the Waldorf-Astoria Hotel in New York City.
There will be a live webcast of the presentation, which will be
accessible through a link available on the home page and investor
relations section of the Allos website.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
committed to the development and commercialization of innovative
anti-cancer therapeutics. Allos is currently focused on the development
and commercialization of FOLOTYNTM (pralatrexate injection),
a folate analogue metabolic inhibitor. FOLOTYN is the first and only
drug approved in the U.S. for the treatment of patients with relapsed or
refractory peripheral T-cell lymphoma. Allos is also exploring the
potential of FOLOTYN in other indications. Allos retains exclusive
worldwide rights to FOLOTYN for all indications. Allos is headquartered
in Westminster, CO. For additional information, please visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional information
concerning these forward-looking statements and other factors that may
cause actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2009 and in the Company's other periodic reports and
filings with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the forward-looking
statements contained in the presentation. All forward-looking statements
are based on information currently available to the Company on the date
thereof, and the Company undertakes no obligation to revise or update
these forward-looking statements to reflect events or circumstances
after the date of these presentations, except as required by law.
SOURCE: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com
